Crohn's disease leading to bowel cancer may be avoided by consumption of soya isoflavones: Adjunct-chemotherapy with oxaliplatin

Medical Hypotheses

Volumn 66, Issue 5, 2006, Pages 934-935

  Wiseman, Alan ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOFLAVONOID; FLUOROURACIL; ISOFLAVONE DERIVATIVE; OXALIPLATIN; PHYTOESTROGEN; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CROHN DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DNA REPLICATION; DRUG MECHANISM; FOOD INTAKE; HUMAN; INTESTINE CARCINOMA; PRIORITY JOURNAL; REVIEW; SOYBEAN; TUMOR CELL;

GLYCINE MAX;

EID: 32144449784     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.11.038     Document Type: Article

References (3)

1. A. Wiseman, and P.S. Goldfarb Oxaliplatin and targeted adjunct chemotherapy for bowel cancer through DNA binding: causal involvement of ROS J Appl Therap Res 5 3 2005 24 31
2. S. Anderton Dissolving boron for cancer therapy Chem World 2 2005 16
3. H. Wiseman Isoflavanoids and human health O. Andersen K. Markham Flavonoids: chemistry, biochemistry and applications 2005 CRC, Taylor & Francis Florida, London (UK) 371 396